Menu
GWAS Study

Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells.

Li J, Jørgensen SF, Maggadottir SM et al.

25891430 PubMed ID
GWAS Study Type
11777 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

LJ
Li J
JS
Jørgensen SF
MS
Maggadottir SM
BM
Bakay M
WK
Warnatz K
GJ
Glessner J
PR
Pandey R
SU
Salzer U
SR
Schmidt RE
PE
Perez E
RE
Resnick E
GS
Goldacker S
BM
Buchta M
WT
Witte T
PL
Padyukov L
VV
Videm V
FT
Folseraas T
AF
Atschekzei F
EJ
Elder JT
NR
Nair RP
WJ
Winkelmann J
GC
Gieger C
NM
Nöthen MM
BC
Büning C
BS
Brand S
SK
Sullivan KE
OJ
Orange JS
FB
Fevang B
SS
Schreiber S
LW
Lieb W
AP
Aukrust P
CH
Chapel H
CC
Cunningham-Rundles C
FA
Franke A
KT
Karlsen TH
GB
Grimbacher B
HH
Hakonarson H
HL
Hammarström L
EE
Ellinghaus E
Chapter II

Abstract

Summary of the research findings

Common variable immunodeficiency disorder (CVID) is the most common symptomatic primary immunodeficiency in adults, characterized by B-cell abnormalities and inadequate antibody response. CVID patients have considerable autoimmune comorbidity and we therefore hypothesized that genetic susceptibility to CVID may overlap with autoimmune disorders. Here, in the largest genetic study performed in CVID to date, we compare 778 CVID cases with 10,999 controls across 123,127 single-nucleotide polymorphisms (SNPs) on the Immunochip. We identify the first non-HLA genome-wide significant risk locus at CLEC16A (rs17806056, P=2.0 × 10(-9)) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome 6p21 (rs1049225, P=4.8 × 10(-16)). Clec16a knockdown (KD) mice showed reduced number of B cells and elevated IgM levels compared with controls, suggesting that CLEC16A may be involved in immune regulatory pathways of relevance to CVID. In conclusion, the CLEC16A associations in CVID represent the first robust evidence of non-HLA associations in this immunodeficiency condition.

778 European ancestry cases, 10,999 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

11777
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Sweden, U.S., Norway, U.K., Germany
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.